By otakuyassine3@gmail.com 
ICON Public Limited (NASDAQ:ICLR – Get Free Report) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 1,520,000 shares, a growth of 14.3% from the November 30th total of 1,330,000 shares. Approximately 1.9% of the company’s shares are short sold. Based on an average trading volume of 1,290,000 shares, the short-interest ratio is presently 1.2 days.
ICON Public Trading Up 0.0 %
ICLR opened at $209.71 on Wednesday. ICON Public has a 12-month low of $183.38 and a 12-month high of $347.72. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The stock has a market capitalization of $17.30 billion, a PE ratio of 23.38, a P/E/G ratio of 1.54 and a beta of 1.21. The firm’s fifty day moving average price is $213.84 and its 200 day moving average price is $277.13.
ICON Public (NASDAQ:ICLR – Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The company had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter last year, the company posted $3.10 EPS. As a group, research analysts expect that ICON Public will post 13.42 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
ICLR has been the subject of a number of research reports. Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th. Evercore ISI decreased their target price on ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Truist Financial reiterated a “buy” rating and set a $284.00 target price (down from $295.00) on shares of ICON Public in a report on Wednesday, December 18th. JPMorgan Chase & Co. decreased their price target on ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Finally, TD Cowen dropped their price objective on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Four analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $289.10.
Read Our Latest Stock Report on ICON Public
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Foyston Gordon & Payne Inc bought a new position in ICON Public during the third quarter worth $11,672,000. Kornitzer Capital Management Inc. KS boosted its holdings in shares of ICON Public by 15.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock valued at $30,016,000 after buying an additional 13,163 shares during the period. Icon Wealth Advisors LLC boosted its holdings in shares of ICON Public by 861.1% in the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after buying an additional 11,840 shares during the period. Sara Bay Financial bought a new stake in shares of ICON Public during the 3rd quarter valued at about $1,143,000. Finally, Crestwood Advisors Group LLC acquired a new stake in ICON Public during the second quarter worth about $288,000. Institutional investors and hedge funds own 95.61% of the company’s stock.
About ICON Public
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
See Also
Receive News & Ratings for ICON Public Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ICON Public and related companies with MarketBeat.com’s FREE daily email newsletter.